Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Iovance Biotherapeutics (IOVA) over the last 15 years, with Dec 2024 value amounting to $12.0 million.

  • Iovance Biotherapeutics' Depreciation & Amortization (CF) fell 2.07% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.2 million, marking a year-over-year increase of 9.82%. This contributed to the annual value of $12.0 million for FY2024, which is 3.45% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Depreciation & Amortization (CF) of $12.0 million as of FY2024, which was up 3.45% from $11.6 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Depreciation & Amortization (CF) registered a high of $12.0 million during FY2024, and its lowest value of $1.1 million during FY2020.
  • Over the past 3 years, Iovance Biotherapeutics' median Depreciation & Amortization (CF) value was $11.6 million (recorded in 2023), while the average stood at $11.0 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Depreciation & Amortization (CF) dropped by 2.48% in 2020, and later soared by 199.26% in 2022.
  • Over the past 5 years, Iovance Biotherapeutics' Depreciation & Amortization (CF) (Yearly) stood at $1.1 million in 2020, then surged by 172.89% to $3.1 million in 2021, then spiked by 199.26% to $9.3 million in 2022, then climbed by 24.60% to $11.6 million in 2023, then climbed by 3.45% to $12.0 million in 2024.